Debromohymenialdisine

Identification

Name
Debromohymenialdisine
Accession Number
DB04367  (EXPT01124)
Type
Small Molecule
Groups
Experimental
Description
Not Available
Structure
Thumb
Synonyms
Not Available
Categories
UNII
Not Available
CAS number
Not Available
Weight
Average: 245.2373
Monoisotopic: 245.091274621
Chemical Formula
C11H11N5O2
InChI Key
JYRJOQGKGMHTOO-VURMDHGXSA-N
InChI
InChI=1S/C11H11N5O2/c12-11-15-8(10(18)16-11)6-2-4-14-9(17)7-5(6)1-3-13-7/h1,3,13H,2,4H2,(H,14,17)(H3,12,15,16,18)/b8-6-
IUPAC Name
5-[(4Z)-8-hydroxy-1H,4H,5H,6H-pyrrolo[2,3-c]azepin-4-ylidene]-2-imino-2,5-dihydro-1H-imidazol-4-ol
SMILES
OC1=NC(=N)N\C1=C1\CCN=C(O)C2=C1C=CN2

Pharmacology

Indication
Not Available
Pharmacodynamics
Not Available
Mechanism of action
TargetActionsOrganism
UActivated CDC42 kinase 1Not AvailableHuman
UDual specificity protein kinase CLK1Not AvailableHuman
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
Not Available
Food Interactions
Not Available

References

Synthesis Reference

David A. Horne, Kenichi Yakushijin, "Intermediates for the synthesis of debromohymenialdisine and processes thereof." U.S. Patent US6197954, issued December, 1987.

US6197954
General References
Not Available
External Links
PubChem Compound
5288032
PubChem Substance
46505283
ChemSpider
4450275
BindingDB
16591
ChEMBL
CHEMBL255465
HET
DBQ
PDB Entries
1u4d / 1z57 / 2c3j / 2cn8

Clinical Trials

Clinical Trials
Not Available

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.146 mg/mLALOGPS
logP-0.16ALOGPS
logP-0.24ChemAxon
logS-3.2ALOGPS
pKa (Strongest Acidic)7.45ChemAxon
pKa (Strongest Basic)5.98ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count6ChemAxon
Hydrogen Donor Count5ChemAxon
Polar Surface Area116.85 Å2ChemAxon
Rotatable Bond Count0ChemAxon
Refractivity76.4 m3·mol-1ChemAxon
Polarizability23.69 Å3ChemAxon
Number of Rings3ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9921
Blood Brain Barrier+0.8326
Caco-2 permeable-0.6093
P-glycoprotein substrateSubstrate0.7497
P-glycoprotein inhibitor INon-inhibitor0.8233
P-glycoprotein inhibitor IINon-inhibitor0.8915
Renal organic cation transporterNon-inhibitor0.6858
CYP450 2C9 substrateNon-substrate0.7773
CYP450 2D6 substrateNon-substrate0.7802
CYP450 3A4 substrateNon-substrate0.5203
CYP450 1A2 substrateNon-inhibitor0.5219
CYP450 2C9 inhibitorNon-inhibitor0.7556
CYP450 2D6 inhibitorNon-inhibitor0.8343
CYP450 2C19 inhibitorNon-inhibitor0.6633
CYP450 3A4 inhibitorNon-inhibitor0.756
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.8794
Ames testNon AMES toxic0.5903
CarcinogenicityNon-carcinogens0.9329
BiodegradationNot ready biodegradable0.9303
Rat acute toxicity2.5770 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9537
hERG inhibition (predictor II)Non-inhibitor0.6592
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as pyrroloazepines. These are compounds containing a pyrroloazepine moiety, which is a bicyclic heterocycle which consists of a pyrrole ring fused to an azepine. Pyrrole is 5-membered ring consisting of four carbon atoms and one nitrogen atom. Azepine is a 7-membered ring consisting of six carbon and one nitrogen atom.
Kingdom
Organic compounds
Super Class
Organoheterocyclic compounds
Class
Pyrroloazepines
Sub Class
Not Available
Direct Parent
Pyrroloazepines
Alternative Parents
Alpha amino acids and derivatives / 2-heteroaryl carboxamides / Azepines / Imidazolinones / Pyrroles / Heteroaromatic compounds / Secondary carboxylic acid amides / Guanidines / Lactams / N-acylimines
show 7 more
Substituents
Alpha-amino acid or derivatives / Pyrroloazepine / 2-heteroaryl carboxamide / Azepine / Imidazolinone / Heteroaromatic compound / 2-imidazoline / Pyrrole / Carboxamide group / Guanidine
show 17 more
Molecular Framework
Aromatic heteropolycyclic compounds
External Descriptors
Not Available

Targets

Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
Ww domain binding
Specific Function
Non-receptor tyrosine-protein and serine/threonine-protein kinase that is implicated in cell spreading and migration, cell survival, cell growth and proliferation. Transduces extracellular signals ...
Gene Name
TNK2
Uniprot ID
Q07912
Uniprot Name
Activated CDC42 kinase 1
Molecular Weight
114567.605 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
Protein serine/threonine/tyrosine kinase activity
Specific Function
Dual specificity kinase acting on both serine/threonine and tyrosine-containing substrates. Phosphorylates serine- and arginine-rich (SR) proteins of the spliceosomal complex and may be a constitue...
Gene Name
CLK1
Uniprot ID
P49759
Uniprot Name
Dual specificity protein kinase CLK1
Molecular Weight
57290.145 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423]

Drug created on June 13, 2005 07:24 / Updated on August 02, 2018 05:20